I09.81 Insurance Policy Changes

ICD-10 I09.81 is officially defined as "Rheumatic heart failure." code I09.81 is referenced in 5 tracked payer policy changes from Excellus BlueCross BlueShield and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code I09.81 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Jun 15, 2026High impact
Pacemakers and Cardiac Resynchronization Therapy (CRT) Devices - (Effective Date - 2026-06-15) 7.01.58
Excellus policy 7.01.58 Pacemakers and Cardiac Resynchronization Therapy (CRT) Devices has a current effective date of June 15, 2026. Its 02/19/26 annual review moved cardiac contractility modulation (CCM) devices to policy 7.01.06, added new indications for upgrade to a CRT-D, added a medically appropriate statement for upgrading a single-chamber ventricular pacemaker (VVI) to a dual-chamber pacemaker (DDD), and added recurrent Adams-Stokes syndrome to the pacemaker indications for recurrent syncope. The update also deleted codes 0408T, 0409T, 0915T, 0916T and 0923T.
Excellus BlueCross BlueShield · Effective Mar 19, 2026Medium impact
Ventricular Assist Device (VAD) and Total Artificial Heart (TAH) 7.01.114
Excellus BlueCross BlueShield policy 7.01.114 covers ventricular assist devices (VADs) and total artificial hearts (TAH) for listed indications. FDA-approved VADs are considered medically appropriate as a bridge to transplant for individuals who meet all listed criteria, including approval as a heart transplant candidate by an approved heart transplant center, imminent risk of dying before donor heart procurement, optimal inotropic support, and an intra-aortic balloon pump unless contraindicated. VADs are also considered appropriate as a bridge to recovery and as destination therapy for adults who meet all listed criteria, such as NYHA Class III or IV heart failure, left ventricular ejection fraction of 25% or less, and inotrope dependence or a cardiac index below 2.2 liters/min/m2. Percutaneous VADs are considered medically necessary for listed indications, including high-risk PCI and short-term circulatory support in cardiogenic shock. A TAH is considered medically appropriate as a bridge to transplant, while a TAH as destination therapy is considered investigational.
Aetna · Identified Aug 14, 2026Medium impact
Intensive Cardiac Rehabilitation Programs (CPB 0267, reviewed 2026-05-14)
Aetna considers intensive cardiac rehabilitation programs (the Benson-Henry Institute Cardiac Wellness Program, the Ornish cardiac treatment program and the Pritikin Program) medically necessary as an alternative to traditional Phase II cardiac rehabilitation for members who meet the cardiac rehabilitation criteria, limited to 72 one-hour sessions, up to 6 per day, over a period of up to 18 weeks. Virtual delivery by real-time audio and video (excluding audio-only) is considered medically necessary when the telehealth program and member criteria are met, but hospital outpatient departments are not eligible for virtual telehealth services. Intensive cardiac rehabilitation is considered experimental, investigational or unproven for diabetes, hyperlipidemia, prostate cancer, metabolic syndrome and all other indications where effectiveness has not been established.
Aetna · Identified Aug 12, 2026Medium impact
Automated Ambulatory Blood Pressure Monitoring (CPB 0025, reviewed 2026-03-12)
Aetna considers automated ambulatory blood pressure monitoring medically necessary when a member meets one of the listed criteria: at least two elevated office readings taken on separate days to identify 'white coat' hypertension; episodic hypertension with symptoms suggesting an adrenal tumor and repeatedly normal office readings; hypotensive symptoms or syncope thought related to antihypertensive medications; syncope evaluated with a 24-hour Holter monitor; nocturnal angina; resistant hypertension before an invasive investigation for secondary causes; or autosomal dominant polycystic kidney disease in children and young adults 30 years of age or younger. Monitoring for less than 24 hours or more than 3 days is not considered medically necessary, and repeat testing is not generally necessary more often than every 6 months. Aetna considers the use experimental, investigational, or unproven for heart failure, for pregnant women who do not meet the criteria, for diagnosing malignant hypertension, for members with an irregular cardiac rhythm such as atrial fibrillation, for routine monitoring to establish a hypertension diagnosis or evaluate treatment response, and for routine use before continuous positive airway pressure (CPAP) therapy.
Aetna · Identified Aug 12, 2026Medium impact
Electrical Bioimpedance for Cardiac Output Monitoring and Other Selected Indications (CPB 0472, reviewed 2026-07-17)
Aetna considers cardiac monitoring with thoracic electrical bioimpedance medically necessary when medical history, physical examination and standard assessment tools provide insufficient information and the treating physician determines the data are necessary, for differentiating cardiogenic from pulmonary causes of acute dyspnea, evaluating rejection in heart transplant recipients as a pre-determined alternative to myocardial biopsy, monitoring response to medication changes for drug-resistant hypertension, optimizing the atrio-ventricular interval in patients with AV sequential pacemakers, optimizing fluid management in congestive heart failure, and outpatient monitoring of continuous inotropic therapy for terminal CHF. Aetna considers electrical bioimpedance for body composition and nutritional status, cancer detection and palliative cancer care, lung capacity screening, sarcopenia, neuromuscular diseases, intracochlear monitoring, fluid balance in end-stage renal disease, and whole-body bioimpedance for cardiac output monitoring in neonates experimental, investigational or unproven. Cardiac monitoring with these devices is also considered experimental, investigational or unproven for congenital heart disease surgery, orthotopic liver transplantation, cardiopulmonary bypass, ischemic heart disease without overt cardiac failure, edema or arrhythmias, and severe aortic regurgitation.

Watch I09.81

Get one email when a payer policy names I09.81, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code I09.81?

There are 5 tracked policy changes affecting code I09.81, including updates from Excellus BlueCross BlueShield, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code I09.81?

Payers that have issued tracked updates for code I09.81 include: Excellus BlueCross BlueShield, Aetna.

How do I get notified when code I09.81 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code I09.81. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code I09.81?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Pacemakers and Cardiac Resynchronization Therapy (CRT) Devices - (Effective Date - 2026-06-15) 7.01.58

Ventricular Assist Device (VAD) and Total Artificial Heart (TAH) 7.01.114

Intensive Cardiac Rehabilitation Programs (CPB 0267, reviewed 2026-05-14)

Automated Ambulatory Blood Pressure Monitoring (CPB 0025, reviewed 2026-03-12)

Electrical Bioimpedance for Cardiac Output Monitoring and Other Selected Indications (CPB 0472, reviewed 2026-07-17)

What insurance policy changes affect code I09.81?

Which payers have updated policy for code I09.81?

How do I get notified when code I09.81 policy changes?

Why do payers change policies for code I09.81?